Patents by Inventor Hector F. DeLuca

Hector F. DeLuca has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10479764
    Abstract: This invention discloses 2-methylene-(22E)-25-hexanoyl-24-oxo-26,27-cyclo-22-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-(22E)-25-hexanoyl-24-oxo-26,27-cyclo-22-dehydro-19-nor-1?-hydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits relatively high transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also shows low activity in vivo on bone calcium mobilization, and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: November 19, 2019
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Hector F. DeLuca, Margaret Clagett-Dame, Lori A. Plum, Rafal Barycki
  • Patent number: 10434110
    Abstract: A method of treating an MS patient with homosalate, octyl salicylate, or a combination is disclosed.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: October 8, 2019
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Hector F. DeLuca, Steven Marling, Lori A. Plum, Yanping F. Wang
  • Patent number: 10369161
    Abstract: Disclosed are methods of administering 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism and/or to treat and/or prevent the symptoms of primary hyperparathyroidism in as subject having or at risk for developing primary hyperparathyroidism, preferably without inducing hypercalcemia in the patient.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: August 6, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Lori A. Plum, Margaret Clagett-Dame
  • Publication number: 20190009104
    Abstract: A method and computer program product for suppressing the symptoms of multiple sclerosis (MS) by irradiating a subject exhibiting the symptoms with a pre-determined dose of UV-containing light from a light source and detecting a suppression of the clinical symptoms of MS. In particular, the detected suppression of the clinical symptoms is disassociated from the vitamin D production within the subject.
    Type: Application
    Filed: September 14, 2018
    Publication date: January 10, 2019
    Inventors: Hector F. Deluca, Bryan R. Becklund
  • Patent number: 10105375
    Abstract: Disclosed are pharmaceutical compositions and methods of combination therapy that include or utilize low doses of 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 and a calcimimetic to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: October 23, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Margaret Clagett-Dame, Lori A. Plum
  • Patent number: 10046000
    Abstract: Disclosed are methods of administering 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: August 14, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Lori A. Plum, Julia B. Zella, Margaret Clagett-Dame
  • Publication number: 20180055856
    Abstract: Disclosed are pharmaceutical compositions and methods of combination therapy that include or utilize low doses of 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 and a calcimimetic to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism.
    Type: Application
    Filed: August 1, 2017
    Publication date: March 1, 2018
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Margaret Clagett-Dame, Lori A. Plum
  • Publication number: 20180015107
    Abstract: A method of treating an MS patient with homosalate, octyl salicylate, or a combination is disclosed.
    Type: Application
    Filed: July 7, 2017
    Publication date: January 18, 2018
    Inventors: Hector F. DeLuca, Steven Marling, Lori A. Plum, Yanping F. Wang
  • Publication number: 20170326159
    Abstract: Oral and topical pharmaceutical compositions, kits and methods of treatment thereof for treating various skin disorder including acne, psoriasis, ichthyosis, photoaging, photodamaged skin, and, skin cancer.
    Type: Application
    Filed: August 3, 2017
    Publication date: November 16, 2017
    Inventors: Margaret Clagett-Dame, Hector F. DeLuca, Nirca J. Nieves, Lori A. Plum, Mary E. Kaiser
  • Patent number: 9814736
    Abstract: Disclosed are methods of administering 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism, including a subject previously administered a calcimimetic.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: November 14, 2017
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Lori A. Plum, Margaret Clagett-Dame
  • Publication number: 20170296558
    Abstract: The invention relates to using 2-methylene-19-nor-(20S)-1?,25-(OH)2D3 (2MD) or 2?-methyl-19-nor-(20S)-1?,25-(OH)2D3 (2AMD) to prevent nephrotoxicity and/or fibrosis in a patient, preferably without causing hypercalcemia in the patient.
    Type: Application
    Filed: March 6, 2017
    Publication date: October 19, 2017
    Inventors: Hector F. DeLuca, Hans W. Sollinger, Bianca Raquel Tomasini-Johansson, Lori A. Plum, Debra Hullett
  • Publication number: 20170253546
    Abstract: Disclosed are 2-methylene analogs of vitamin D3 and related compounds, their biological activities, and various pharmaceutical uses for these analogs. Particularly disclosed are 1?-hydroxy-2-methylene-vitamin D3, (20S)-1?-hydroxy-2-methylene-vitamin D3, and (5E)-1?,25-dihydroxy-2-methylene-vitamin D3, their biological activities, and various pharmaceutical uses for these compounds including methods of treating and/or preventing bone diseases and disorders.
    Type: Application
    Filed: May 18, 2017
    Publication date: September 7, 2017
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Izabela K. Sibilska, Rafal R. Sicinski, Lori A. Plum
  • Publication number: 20170252360
    Abstract: Disclosed are methods of administering 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism.
    Type: Application
    Filed: May 24, 2017
    Publication date: September 7, 2017
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Lori A. Plum, Julia B. Zella, Margaret Clagett-Dame
  • Publication number: 20170246206
    Abstract: A calcium formate composition for oral administration to an individual for the purpose of supplementary dietary calcium is disclosed.
    Type: Application
    Filed: May 16, 2017
    Publication date: August 31, 2017
    Inventor: Hector F. DeLuca
  • Patent number: 9717744
    Abstract: Disclosed are methods of administering 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: August 1, 2017
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Lori A. Plum, Julia B. Zella, Margaret Clagett-Dame
  • Patent number: 9688596
    Abstract: Disclosed are 2-methylene analogs of vitamin D3 and related compounds, their biological activities, and various pharmaceutical uses for these analogs. Particularly disclosed are 1?-hydroxy-2-methylene-vitamin D3, (20S)-1?-hydroxy-2-methylene-vitamin D3, and (5E)-1?,25-dihydroxy-2-methylene-vitamin D3, their biological activities, and various pharmaceutical uses for these compounds including methods of treating and/or preventing bone diseases and disorders.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: June 27, 2017
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Izabela K. Sibilska, Rafal R. Sicinski, Lori A. Plum
  • Publication number: 20170049808
    Abstract: A calcium formate composition for oral administration to an individual for the purpose of supplementary dietary calcium is disclosed.
    Type: Application
    Filed: November 3, 2016
    Publication date: February 23, 2017
    Inventor: Hector F. DeLuca
  • Publication number: 20170042913
    Abstract: Disclosed are methods of administering 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism, including a subject previously administered a calcimimetic.
    Type: Application
    Filed: October 31, 2016
    Publication date: February 16, 2017
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Lori A. Plum, Margaret Clagett-Dame
  • Publication number: 20170036977
    Abstract: Disclosed are 2-methylene analogs of vitamin D3 and related compounds, their biological activities, and various pharmaceutical uses for these analogs. Particularly disclosed are 1?-hydroxy-2-methylene-vitamin D3, (20S)-1?-hydroxy-2-methylene-vitamin D3, and (5E)-1?,25-dihydroxy-2-methylene-vitamin D3, their biological activities, and various pharmaceutical uses for these compounds including methods of treating and/or preventing bone diseases and disorders.
    Type: Application
    Filed: July 26, 2016
    Publication date: February 9, 2017
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Izabela K. Sibilska, Rafal R. Sicinski, Lori A. Plum
  • Patent number: 9539264
    Abstract: Disclosed are methods of administering 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism, including a subject previously administered a calcimimetic.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: January 10, 2017
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Lori A. Plum, Margaret Clagett-Dame